Results of Operations and Financial Condition. On August 14, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.

Entry into a Material Definitive Agreement. On May 20, 2026, Annovis Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”), dated as of May 20, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”) (i) an aggregate of 7,895,000 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and (ii) acco…

Results of Operations and Financial Condition. On May 15, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.

Entry into a Material Definitive Agreement. Underwritten Registered Direct Offering On April 9, 2026, Annovis Bio, Inc. (the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of April 9, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in an underwritten registered direct offering (the “Offering”) (i) an aggregate of 5,263,156 shares of common stock (the “Shares”), $0.0001…

Chief Financial Officer — Mark Guerin: Mr. Guerin is no longer employed as Chief Financial Officer.

Results of Operations and Financial Condition. On March 16, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.

Results of Operations and Financial Condition. ​ On November 12, 2025, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference. ​

Other Events. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Loeb & Loeb LLP, regarding the validity of the Shares, the Placement Agent Warrant, and the shares underlying the Placement Agent Warrants being registered, which opinion is attached hereto as Exhibit 5.1 and is incorporated herein by reference.

Entry into a Material Definitive Agreement. Registered Direct Offering On October 26, 2025 (the “Agreement Date”), Annovis Bio, Inc. (the “Company”) entered into (i) a Securities Purchase Agreement (the “Purchase Agreement”), with the purchasers signatory thereto (the “Purchasers”) pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) an aggregate of 597,561 shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”…

Other Events. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Loeb & Loeb LLP, regarding the validity of the Shares, the Pre-Funded Warrants, the Placement Agent Warrant, and the shares underlying the Pre-Funded Warrants and the Placement Agent Warrants being registered, which opinion is attached hereto as Exhibit 5.1 and is incorporated herein by reference.

Entry into a Material Definitive Agreement. Registered Direct Offering On October 10, 2025 (the “Agreement Date”), Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”), with the purchasers signatory thereto (the “Purchasers”) pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) an aggregate of 3,150,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “…

Chief Financial Officer — Mark Guerin: The company appointed a new Chief Financial Officer from an external candidate.

Vice President of Finance (Principal Financial Officer) — Andrew Walsh: Mr. Walsh resigned from his position as Vice President of Finance and Principal Financial Officer.

Results of Operations and Financial Condition. On August 12, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.

Principal Financial Officer — Andrew Walsh: Andrew Walsh was promoted to Principal Financial Officer from Vice President of Finance.

Results of Operations and Financial Condition. On May 13, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.

Interim Chief Financial Officer — William Fricker: Mr. Fricker will no longer serve as interim Chief Financial Officer.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 26, 2025, Annovis Bio, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50…

Results of Operations and Financial Condition. On March 21, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the fourth quarter and the fiscal year ended December 31, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.

Entry into a Material Definitive Agreement. On February 3, 2025, Annovis Bio, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with ThinkEquity LLC, acting as representative of the underwriters (“ ThinkEquity ”) with respect to an underwritten public offering of 5,250,000 units of the Company, each unit consisting of one share of its common stock, par value $0.0001 per share (the “ Common Stock ”) and one warrant to purchase one share of the Compa…

Entry into a Material Definitive Agreement. On December 11, 2024, Annovis Bio, Inc. (the “ Company ”) entered into an Equity Distribution Agreement (the “ Distribution Agreement ”) with Oppenheimer & Co. Inc., serving as agent (“ Oppenheimer ”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “ Common Stock ”), having an aggregate offering price o…

Chief Financial Officer (Interim) — William Fricker: Annovis Bio appointed William Fricker as Interim Chief Financial Officer.

Results of Operations and Financial Condition On November 11, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.

Results of Operations and Financial Condition On August 15, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.

Regulation FD Disclosure On July 16, 2024, Annovis Bio, Inc. (“The Company”) issued a press release announcing FDA approval to transition to its new crystal form of Buntanetap for future clinical trials. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.